Skip to main content

Cetuximab News

ASCO: Encorafenib + Cetuximab + Chemo Lengthens Survival in Metastatic CRC

FRIDAY, May 30, 2025 – For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus...

Dual-Targeted Therapies Plus Chemo Improve Objective Response Rate in BRAF V600E Metastatic CRC

TUESDAY, Feb. 4, 2025 – For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard chemotherapy (modified folinic acid [or levofolinate],...

There's a Best Option for Patients With Head-and-Neck Cancer Who Can't Take Cisplatin

TUESDAY, Nov. 26, 2024 – Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but nearly a third of patients can't tolerate its side effects and quit the drug. A new trial...

FDA Approves Erbitux to Treat Late-stage Head and Neck Cancer

SILVER SPRING, Md., Nov. 7, 2011 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Colorectal Cancer, Non-Small Cell Lung Cancer

Cetuximab patient information at Drugs.com